EP0858327A2 - Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies - Google Patents

Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies

Info

Publication number
EP0858327A2
EP0858327A2 EP96931214A EP96931214A EP0858327A2 EP 0858327 A2 EP0858327 A2 EP 0858327A2 EP 96931214 A EP96931214 A EP 96931214A EP 96931214 A EP96931214 A EP 96931214A EP 0858327 A2 EP0858327 A2 EP 0858327A2
Authority
EP
European Patent Office
Prior art keywords
mea
administration
cells
transfer factor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96931214A
Other languages
German (de)
English (en)
Inventor
Samir Chachoua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0858327A2 publication Critical patent/EP0858327A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the present invention is directed to new therapeutic compositions and applications of 2-mercaptoethanolamine (2-MEA) and related aminothiols and di-isopropyl salicylates, solely or in combination with other factors, agents, or processes that are physical, chemical and/or biological based, including precursors, intermediates, end products, catalysts, promoters and/or any factors, agents, or processes involved directly or indirectly from initial application of the therapy to the final result. More particularly, the present invention is directed to the use of 2-MEA and related aminothiols and copper(II)-3,5 di-isopropyl salicylate in the treatment and prevention of AIDS, cancer, autoimmune disease, microbiological infections, and other diseases where immunological dysfunction and/or free radical formation function as part of the disease mechanism.
  • 2-MEA 2-mercaptoethanolamine
  • related aminothiols and di-isopropyl salicylates solely or in combination with other factors, agents, or processes that are physical, chemical and/or biological based, including precursors, intermediate
  • 2-MEA has long been used by itself in the treatment of kidney disease, known as cysteinuria, where it may protect renal function.
  • 2-MEA and related compounds have also been used as radiation protective agents in various formulations. This is at least due in part to the powerful antioxidant properties of these compounds.
  • 2-MEA has also been linked with ulcerogenic properties in animal experiments.
  • 2-MEA has been shown to exert both immunostimulant and immunomodulant action in in vitro trials. Jeitner et al, Biochimica et Biophysica Acta 1223:15-22 (1994). Cystamine, a related compound, has demonstrated in vitro inhibition of HIV. Bergamini et al, J. Clin. Invest. 93:2251-2257 (1994).
  • Other applications of 2-MEA have been in the field of non-specific vitamin supplementation as a general antioxidant supplement in Swedish Anti- Aging
  • 2-MEA and related aminothiols are used in cancer prevention and treatment as a general immunostimulant and/or as an antioxidant to offset some of the toxic sequelae of the disease condition or other conventional therapies such as chemotherapy and radiotherapy. It is important in the application of 2-MEA and related aminothiols to either bind the compound to a delivery system which directs its protective action preferentially to healthy cells and/or time its delivery so as not to interfere with the anticancer activity of the therapy.
  • a therapy may be beneficial to the body and antagonistic to the disease if timed correctly. If antioxidants like 2-MEA, for example, are timed correctly so as to inhibit or otherwise interfere with agents used in therapy which generate free radicals, then the previously antagonistic therapy may now protect disease by interfering with therapy and may now be classified as synergistic.
  • 2-MEA 2-MEA and related aminothiols including penicillamine and/or copper(II)-3,5-di-isopropyl salicylate were administered to patients as single agents, or in combination with other factors, agents, or processes which induced, stimulated, and/or facilitated their efficacy, or inhibited, suppressed or neutralized their toxic or undesired effects. Some agents and factors may have dual capabilities.
  • 2-MEA and related aminothiols may be incorporated in many uses requiring its antioxidant capabilities of other properties, the present invention is directed primarily to the medical applications of 2-MEA.
  • the use of 2-MEA in the present invention impacts on diseases as varied as AIDS, systemic lupus erythromatosus, cancer, arthritis, autoimmune diseases, and can be used in sunscreens to minimize radiation damage.
  • Cimetidine may directly aid in the immunostimulating or immunomodulating action of 2-MEA while inhibiting ulcer formation.
  • Copper(II)-3,5 di-isopropyl salicylate directly supports the antioxidant ability of 2-MEA while indirectly assisting in the treatment of cancer, for example, by having its own anti-cancer activity.
  • a therapeutic composition and method for using 2-MEA and related aminothiols in the treatment and prevention of AIDS, cancer, autoimmune diseases, and microbiological infections, comprising the step of administering an effective dosage of a therapeutic composition comprising 2-MEA or related aminothiols to a patient having AIDS, cancer, autoimmune disease, microbiological infections, and other diseases where immunological dysfunction and/or free radical formation function as part of the disease mechanism.
  • the effective dosage of 2-MEA or related aminothiols for administration to a patient is between approximately O.Olmg and about 500mg, at least once daily, up to four times a day. However, benefits may be achieved with a single dose, a monthly dose or a weekly dose.
  • the therapeutic composition is administered to a patient by a means selected from the group consisting of oral administration, catheter administration, intramuscular administration, intravenous administration, intradermal administration, intradural administration, intravesical administration, intraurethral administration, intrathecal administration, inhalation, topical administration, sub-cutaneous administration, and rectal administration or any other means of administration.
  • the composition is orally administered in a form selected from the group consisting of a capsule, gel cap. liquid, tablet.
  • 2-MEA and related aminothiols were combined with a living biological delivery system.
  • 2-MEA or related aminothiols were incubated with a living biological system to form a mixture.
  • the mixture was centrifuged to produce a pellet comprising the 2- MEA, the active ingredient, bound with the living biological system.
  • the pellet may also include intermediates and/or end products of 2-MEA or related aminothiols depending on the precursor used.
  • the pellet was administered as is or, was re-suspended and washed at least once. The pellet was then administered to patients.
  • the living biological system is selected from the group consisting of yeast, lactic acid cultures, target cells, and other living cells.
  • 2-MEA or related aminothiols and the living biological system were incubated between about 6 hours and about 72 hours depending on the type of living biological system.
  • yeast or yogurt cultures were incubated between about 6 hours and about 48 hours
  • lactic acid cultures were incubated between about 24 and about 48 hours
  • target cells and other living cells were incubated between about 24 and 72 hours.
  • the centrifuging step was performed from about 200 to about
  • the pellet can be administered to patients in several ways. First, the pellet can be orally administered. The pellet can be suspended in a yogurt medium and then applied topically to the skin of the patient. Further, the pellet can be lyophilized and then administered to the patient.
  • a therapeutic composition also called the complex formula is provided comprising therapeutic dosages of 2- MEA or related aminothiols, at least one antioxidant such as BHT, at least one transfer factor of the type developed by the inventor and disclosed herein below, and at least one living organism.
  • Copper(II)-3,5 di-isopropyl salicylate may be included in the complex formulation in place of the 2-MEA or as an additional component.
  • the 2-MEA or copper compound or the complex formula can inactivate and stabilize the presentation of the targeted condition, thereby minimizing the number of multiphasic steps needed in the neutralization of anticipated resistance.
  • a therapeutic composition and method for using copper(II)-3,5 di-isopropyl salicylate in the treatment and prevention of AIDS, cancer, autoimmune diseases, and microbiological infections, comprising the step of administering an effective dosage of a therapeutic composition comprising copper(II)-3.5 di-isopropyl salicylate to a patient having AIDS, cancer, autoimmune disease, microbiological infections, and other diseases where immunological dysfunction and/or free radical formation function as part of the disease mechanism.
  • the effective dosage of copper(II)-3,5 di-isopropyl salicylate for administration to a patient is between approximately lOmg and about 500mg, three times a day.
  • Administration of the composition to a patient is accomplished in the same ways as previously described for 2-MEA, and is orally administered in the same forms as 2-MEA.
  • copper(II)-3,5 di-isopropyl salicylate was combined with a living biological delivery system using the same method steps and same living biological systems as described for 2-MEA. Copper(II)-3,5 di-isopropyl salicylate and the living biological system were incubated between about 6 hours and about 72 hours depending on the type of living biological system.
  • the pellet further included intermediates and/or end products of copper (I I)- 3, 5 di-isopropyl salicylate.
  • the centrifuging step was performed from about 200 ⁇ m to about 50.000 ⁇ m. Different centrifugation rates isolate specific components. Ultracentrifugation was sometimes employed after lysis of cell to recover and concentrate organelles and other fractions for use in the invention.
  • the pellet was administered orally to the patient, suspended in a yogurt medium and applied topically to the skin of the patient, or lyophilized and then administered to the patient.
  • the therapeutic composition comprising an effective dosage of 2-MEA further includes an effective dosage of at least one antioxidant.
  • at least one antioxidant is selected from the group consisting of BHT. BHA. ethoxyquin, TBHQ, nordihydroguaracetic acid, lipoic acid, and vitamin C.
  • the effective dosage of BHT for administration ranges between about 0.01 and about 2% of the dietary intake by patient weight.
  • the therapeutic composition comprising 2-MEA may further include an effective amount of at least one transfer factor in type and/or target.
  • the effective dosage of the transfer factor for administration purposes ranges between about lmg and about 5g per day.
  • the transfer factor is selected from the group consisting of transfer factor of resistance, transfer factor of synergy, and transfer factor of anticipation.
  • the therapeutic composition may further include an effective dosage of living microorganisms selected from the group consisting of acidophilus. theophilus, thermophilus, lactobacillus bulgaricus, lactobacillus plantarum, yeast, kefir and rhizopus.
  • living microorganisms selected from the group consisting of acidophilus. theophilus, thermophilus, lactobacillus bulgaricus, lactobacillus plantarum, yeast, kefir and rhizopus.
  • One yeast that was used in the present invention was saccharomyces cerevisiae.
  • the present invention is directed to the use of 2-MEA and related aminothiols and copper(II)-3,5 di-isopropyl salicylate in the treatment of individuals with AIDS, cancer, microbiological infections and other immune deficient conditions as an adjunct to chemotherapy or radiotherapy, as a broad spectrum antioxidant substance for life extension, in combination with other compounds, or by itself.
  • the effects of 2-MEA and copper(II)-3,5 di-isopropyl salicylate may be enhanced in combination with other compounds which function in one of several ways: 1) augment the effect of the compounds; 2) neutralize their side-effects; and/or 3) alter the targeted condition directly.
  • 2-MEA in combination with cimetidine (Tagamet ® ) or other comparable stomach pain relievers reduces the likelihood of ulcers commonly associated with the use of 2-MEA, an ulcerogenic compound.
  • 2-MEA was also combined with certain antibiotics to neutralize the ulcerogenic side-effects of 2-MEA.
  • Vaccination and antibiotics against heliobacter pylori and other ulcer-related organisms may be combined with 2-MEA to minimize ulcerogenic potential.
  • antioxidants In augmenting the efficacy of 2-MEA, a wide range of antioxidants was used including but not limited to vitamins C and E, beta-carotene, supplements such as pycnogenol, selenium, germanium, nordihydroguaracetic acid, dimethyl sulfoxide, other natural or artificial antioxidants such as copper(II)-3,5 di ⁇ isopropyl salicylate, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ethoxyquin, TBHQ, oxygen peroxide, folic acid or any antioxidant.
  • BHT butylated hydroxytoluene
  • BHA butylated hydroxyanisole
  • oxygen peroxide folic acid or any antioxidant.
  • the antioxidants helped to eliminate the free radicals, which are directly or indirectly generated by a number of disease conditions.
  • 2-MEA acts on cells, and then the intermediates were extracted from the cells.
  • the 2- MEA was also added to target cells like skin cells, immune cells, etc. and then extracted from the target cells, thereby carrying the intermediates, activating factors, co-factors and other components which were activated by 2-MEA.
  • 2- MEA has many functions, including one as an immune stimulator.
  • a preferred method for using 2-MEA in a way that will enhance its immune functions upon administration to a patient is to use 2-MEA as well as its extracts from target cells.
  • the extracts include genetic changes, enzymatic changes as well as activation factors.
  • the present invention provides a method by which induced and amplified changes by 2-MEA are used to enhance the immunological and the antioxidant capacity of 2-MEA upon administration in vivo or in vitro to a patient or desired host system including animals.
  • the 2-MEA and related aminothiols including penicillamine were administered at all stages of the disease conditions tested at a dosage between about O.Olmg and about 500mg, at least daily up to 4 times daily.
  • 2-MEA dosages varied widely.
  • the 2-MEA acted on the target cells, the cells then produced genetic information for cellular multiplication and expansion. For example, 0.1 mg to about l OOmg or more of the transfer factor extracted from the activated target cells was an adequate daily dose to give patients. It was also found that white blood cells removed from a patient and incubated with 2-MEA caused cellular multiplication. The incubated cells were then injected back into the patient.
  • the combination of the white blood cells and the 2-MEA produced a variety of extracts, transfer factors, precursors, etc. All of these products were capable of being administered back into the respective patients for treatment purposes. In the alternative, each of these products were broken down chemically, physically or biologically and the extracts therefrom were administered to the patients.
  • 2-MEA may cause genetic, enzymatic, and other changes in the immune cells, which augment their efficacy and numbers. At the same time. 2-MEA may inhibit mutation and resistance in the targeted condition, for example, inhibition of viral replication in HIV.
  • Sparing function is unique to pharmacology, and is defined by the inventor as the optimal bioavailability and efficacy of a compound being facilitated by induction of secondary changes stimulated by the compound prior to its administration.
  • 2-MEA will induce cellular multiplication and changes on various levels of cellular function. A fraction of the administered dose is used in the induction of these changes, leaving less of the 2-MEA to carry out its primary and other functions in its original form.
  • copper ⁇ II ⁇ -3,5 di-isopropyl salicylate will induce the formation of superoxide dismutase amongst other cellular changes. A fraction of the copper(II)complex will be used up in this induction, leaving less of the original form to carry out its primary antioxidant and other functions.
  • 2-MEA was used in combination with other traditional medical therapies.
  • Viral inhibitors dideoxyinosine (DDI).
  • AZT, protease inhibitors, etc. and other agents combine effectively with 2-MEA as it affects viral replication at different sites.
  • 2-MEA exhibited a very powerful multiplication, immunostimulating and immunomodulating activity.
  • much greater efficacy against the virus was achieved with 2-MEA, leading to a rapid rise and normalization of T-cell parameters accompanied by a sustained drop in PCR.
  • Lower dosages of drugs like AZT were required and much less toxicity occurred.
  • a much greater duration in the efficacy of the other therapeutic agents occurred in the presence of 2-MEA.
  • 2-MEA was combined with ozone, an oxidant.
  • 2-MEA When ozone is at its maximum peak, 2-MEA is not; when 2-MEA is at its maximum peak, ozone is not.
  • the rationale for the combination 2-MEA and ozone therapy is to have 2-MEA inactivate the intracellular virus so that the virus and the cells are prevented from dividing.
  • Ozone kills viruses in the bloodstream.
  • the ozone is pulsed for a specific time period ranging from hours to days apart followed by 2-MEA therapy. Improvement was still observed when the modalities were used simultaneously, but interference also occurred. Each therapy is alternated so that 2-MEA is administered one day and the ozone therapy is given the following day.
  • Ozone was administered by IV, orally, intramuscularly, by enema, etc.
  • 2-MEA acts by entering the patient's cells and preventing the ozone from activating the virus. Viruses need oxidized components to grow inside cells. Ozone kills viruses in the blood. Ozone is capable of killing viruses outside the cells. The general idea with this combination therapy was to have an agent enter the cell while another agent killed the viruses in the bloodstream. This was achieved in several ways. First, medical equipment like infusion pumps pump blood into a chamber where it is ozonized, and then returned back into the patient ' s body. The inventor found that it did not matter how much 2-MEA was in the body, if you blast it with ozone, the viruses were killed.
  • Ozone therapy and 2-MEA can also be combined and then pulsed into the body.
  • Ozone therapy is currently one of the most common AIDS therapies.
  • the ozone itself is inexpensive, but the procedure and equipment are quite costly.
  • ozone is effective for only a short period of time because of its toxicity. Almost everything that damages the body occurs when large amounts of free radicals are released.
  • Ozone acts locally and spontaneously, so when the cells are protected by 2-MEA in the body, ozone produces damaging effects against the targeted disease without damaging the patient's normal cells.
  • the inventor developed a therapeutic kit, which combines a therapeutically effective dosage of 2-MEA in any form with an ozone preparation and a vaccine preparation.
  • the 2-MEA offsets the ozone's damaging effect on the cells.
  • 2-MEA augments the ozone damaging effect against the targeted disease.
  • 2-MEA functions by augmenting the ozone effect not only against HIV, but also against other viral and microbial infections.
  • 2-MEA amplifies the immune response which ozone by itself cannot achieve. While ozone may cause problems with vaccines by restricting some portion of the immune response and thereby damage the vaccine, adding 2-MEA to the vaccine protected it against the ozone ' s deleterious effects.
  • 2-MEA was found to augment the human immune response to the AIDS vaccine and, therefore, serves as a potential adjunct to immunotherapy for any viral or microbial disease. Injection of 2-MEA produced a more immediate and systemic effect, and caused less problems for individuals with ulcers by not passing through the stomach.
  • the genetic information either protected white blood cells and the enzymatic information from the intermediates, and end products of the healthy white blood cells, can be used to selectively protect them, as opposed to 2-MEA which also protects the cancer cells. If amplified genetics are used, you might be able to protect the white blood cells without necessarily protecting the cancer cells because the genetic information would be translated by the cancer cells.
  • Transfer factors cause the activation of T-cells to attack the HIV.
  • transfer factor By raising a transfer factor against HIV in an animal system, that animal produces a simple transfer factor which causes the T-cells to increase in number and attack the HIV.
  • Transfer factor can be raised against live HIV and trigger the immune system to attack the live virus. A transient increase in T- cells occurs and when they die, a drop in the T-cells occurs.
  • Transfer factor of resistance involves taking a transfer factor, for example, from a horse which is resistant to AIDS, and add it to a test tube containing about 10,000 human or the patient's own T-cells. The AIDS virus is then added to the test tube. Of those approximate 10,000 T-cells which accept the transfer factor, most will attack the AIDS virus and die. However, some of the T-cells will accept a special part of the transfer factor of resistance, attack the AIDS virus and not die.
  • Procedurally incubate the surviving human T-cells having the transfer factor from the resistant animal with general human T- cells or even with the patient's own T-cells. Then culture the surviving T-cells because these cells have developed resistance to HIV.
  • This step can be performed in one of two ways. One approach is to obtain more T-cells from the patient, incubate them with the transfer factor of resistance, and then administer them back into the patient. In the alternative, remove T-cells from pooled human blood, incubate them with the transfer factor of resistance, and then administer them to the preselected patients. In yet another approach, inject the transfer factor of resistance into an animal, and allow the animal to amplify the transfer factor. Next, extract the transfer factor from the animal's blood, and then administer the transfer factor into the patient.
  • a second type of transfer factor is transfer factor of synergy, and refers to the time period during which T-cells and PCR loads both rise in the patient's body. Over a period of about 2-3 months, the PCR load and T-cells counts were examined by the inventor on a daily basis. Although prior to the present invention, it was believed that as AIDS patients started to deteriorate. T-cells went down and the viral load increased, the inventor found otherwise. In fact, in quite a number of conditions and several days a month, the relationship was just the opposite. In fact, the T-cells were found to increase as well as the PCR load. Similarly, the T-cells also decreased as well as the PCR load. Sometimes, the PCR decreased and the T-cells increased, or the PCR increased and the T-cells decreased. At times, studies showed the rise between T-cell counts and PCR counts almost parallel.
  • a vaccine was duplicated which made the T-cells and the PCR increase together. Doubling of PCR would accompany similar increases in T-cell counts with certain staphylococcal extract vaccines. Certain phages of staphylococci could cause the T-cells to increase with variable effects on PCR.
  • these T-cells possessed a transfer factor of synergy. When this transfer factor of synergy was extracted out of the T-cells and incubated with the HIV virus or if a vaccine was used to raise them both together and incubated them with HIV. HIV still grew in those cells, but did not kill them.
  • transfer factor of resistance does not allow for the amplification of the virus, so in vitro you do not get viral growth.
  • transfer factor of synergy allows the virus to grow in harmony with the T-cells.
  • the virus can divide in two ways. First, it can grow in the cell and cause it to explode. Secondly, it is believed that the HIV virus divides by budding off the T-cell membrane. The second option is compatible with cell survival.
  • a third transfer factor is transfer factor of provirus (TFP).
  • T-cells from an AIDS patient were removed, amplified in a horse or chicken, and then readministered to the patient when his supply became depleted.
  • the TFP from these same white blood cells was amplified in an animal, and then readministered to the patient.
  • transfer factor is amplified, it is not known what type of transfer factor is produced as the end result.
  • the transfer factor was amplified and added to the patient's white blood cells in a test tube, the T-cells grew.
  • Secondary amplification can then take place in vivo or in vitro.
  • a transfer factor was removed from the white blood cells and then amplified in an animal in vivo. The amplified transfer factor was then added to the animal's provirus T- cells in vitro. Transfer factor of provirus was added to non-infected T-cells along with HIV, and then cultured together. The inventor found that the T-cell count did not drop over 24-48 hours, and the HIV count did not increase or amplify either.
  • a transfer factor extracted from a cell that is actively dying is a transfer factor of disease rather than a transfer factor of resistance. If 100 cells are infected with AIDS and most die, they release transfer factors of sensitivity, not transfer factor of resistance. If 100 cells become infected with AIDS and most survive, a transfer factor of resistance has been produced.
  • Transfer factor of sensitivity is used because one can alter the cells of the patient with transfer factor of sensitivity in vitro, then vaccinate the patient against that so that the cells never get a chance to multiply, expand or put out their transfer factor which will influence other cells.
  • the sensitive part of the system can be stopped from being amplified. For every transfer factor that is good, there is a transfer factor that is deleterious. The idea is to isolate the negative transfer factor only to prevent it from generating and spreading to other cells.
  • transfer factor is transfer factor extracted from animals. Transfer factor from a horse is used because a horse is not susceptible to AIDS or HIV. If you vaccinate the horse against the targeted disease, remove the transfer factor and treat the patient with the horse transfer factor, the transfer factor will activate the patient's T-cells just the same way they did the horse, but the horse's T-cells are resistant to HIV and the human ones are not. They will attack the virus and die.
  • the only way to make the transfer factor of the prior art viable is to use with the transfer factor of activity a transfer factor of resistance. One has to find the cells that will accept, not only increased activity from the horse, but also increased resistance from the horse. Unless cells are given amplified transfer factor of resistance, they will succumb to the infection.
  • Animal cells may resist HIV infection by virtue of superior immune function to human and/or by the lack of receptors to which HIV may attach and enter cells.
  • transfer factor of resistance Another way of preventing this outcome is by using transfer factor of resistance.
  • Another approach is to look for another cell type other than the targeted response cell, the T-cell. It is assumed that because the T-cells attack HIV. the T-cells need to be stimulated against HIV. But, animals do not have a first response against HIV with T-cells. Instead, their first response is with neutrophils.
  • AIDS patients have many neutrophils. They individuals have a large amount of neutrophils because the neutrophils are not attacked by HIV, and neutrophils are resistant to HIV. If you vaccinate an animal with HIV and it responds with a neutrophil attack, the transfer factor from the neutrophils can then be used to arm human neutrophils against HIV. What has been done is that part of the immune system is armed against the HIV virus that has not been seen before. But now that the transfer factor was used to activate it, the virus can be attacked by a part of the immune system that cannot succumb to the virus. These transfer factors are called curative transfer factors.
  • transfer factor In carrying out the method of producing transfer factor and activating the immune system, a large amount of transfer factors were isolated from a horse against cancer cells, simply by injecting the horse with cancer cells. The immune response occurred with neutrophils within 3 hours following the injection. Extraction was usually performed within 2-3 weeks following the injection. However, if you wait this long, you actually miss the most effective transfer factor, which is produced about 3-6 hours after the first injection.
  • the isolated transfer factor can be used in several ways. First, you can activate the part of the human immune system designed to respond to HIV and, if you activate that part, you have to use a transfer factor of resistance to make sure that your new response is also resistant. In the alternative, you proceed to a part of the immune system that is not designed in the human to attack HIV, learn how to activate that part of the immune system in an animal, and isolate the animal's transfer factor.
  • a third option is to take a mixture of transfer factors of resistance, anticipation, provirus, synergy, neutrophils, T-cells, of early, intermediate and late response etc. from all the white blood cells in an animal and expose it to mixed white blood cells from humans or, even better, from the patient.
  • Standard transfer factor manufacturing processes may be augmented by physical, chemical or biochemical stimulation of white blood cell division prior to the extraction process.
  • Phages may cause amplification both before the extraction process and afterwards by at least stimulating division of responsive target cells. Phages stimulate amplification of the target cells, and will uptake and amplify the transfer factor. Phages may also extend the target cell beyond the Hayflick limit. Transformation factors work differently than transfer factors. For example, you can produce transformation factors which are like a transfer factor from neutrophils which are capable of transforming T-cells into resistant parts of the immune system against HIV. In contrast to transfer factors, transformation factors are factors extracted out of one cell type that are capable of causing a change in another cell type. Neutrophils were used to extract transformation factors. Transformation factors will also transform target cells into resistant cells.
  • transformation factor was isolated from white blood cells and used to activate red blood cells and from neutrophils to activate lymphocytes. Unlike transfer factors, transformation factors also have a strong capacity for being curative. The further down the specie level you descend from the human system, the more likely that transformation factors are being used instead of transfer factors, and the less likely one will encounter human analogs in the animals specie. In other words, the more primitive the animal, the more likely that a transformation factor is involved.
  • Anticipatory transfer factor has never been considered in the prior art to the knowledge of the inventor. It is useful because, for example, if you vaccinate a child against measles, mumps, or other childhood diseases, you have the risk of the child succumbing to a long-term side effect of the vaccine itself. The child may develop sub-acute sclerosing panencephalitis for example.
  • Pretreating the patient with an anticipatory transfer factor against the vaccine will most likely achieve the following: a) minimize the time needed to develop immunity because of the prior exposure; b) may obviate the need for a living vaccine because the living vaccines are dangerous ⁇ you can use a killed vaccine if you amplify the immune response with transfer factor ⁇ ; c) may even obviate the use of vaccines.
  • the best anticipatory transfer factor is made of the patient's own cells. The best way to vaccinate someone with minimal risk is to remove their blood, expose it to the targeted agent, and then isolate the transfer factor from the mixture and re-administer it to the patient or mix autogenous blood with transfer factor and re-introduce into the patient.
  • One problem is that animals do not become infected with the HIV to produce AIDS.
  • a preferred system is to use the patient's own cells in vivo where they are exposed in a short burst to 2-
  • the changed virus is isolated, and the transfer factor and transformation factors raised against the changed virus.
  • the transfer factor is then administered back to the patient after about 1 -2 days when the 2-MEA has washed out of his system. The result is vaccinating the patient against how the virus is going to look when 2-MEA is reintroduced into his system. Use the transfer factor and vaccine that was raised against the transformed virus for about 2-3 weeks when the immune response is adequate. Then start the patient on the 2-MEA.
  • AZT and protein inhibitors are not innocuous agents; they have their own side effects.
  • a better approach is to keep these drugs in reserve and start treatment with an innocuous agent like 2-MEA first. After you elicit the maximum immunological response from 2-MEA and related aminothiols. and then administer 2-MEA in combination with AZT, then 2-MEA, AZT plus DDI, singly or in combination, to maximize the length of time of the anticipatory changes and the initiating therapy. With 2-MEA, it is harder to induce a change because 2-MEA does not affect the virus directly like most other agents.
  • 2-MEA affects the virus indirectly by optimal intracellular antioxidation of the cytoplasm, which prevents the membrane or outer wall of the virus from being built because viruses need oxidized co-factors.
  • 2-MEA therefore, affects the host cell more so than the virus itself, and the virus would have to adapt to a change in its environment to its host cell rather than to a direct attack. Viruses can respond better to a direct attack than to a change in the cell environment.
  • the change in the environment also means that 2-MEA may not be able to prevent the insertion of virus into a cell, but it can prevent its proper replication in a cell, so 2-MEA exhibits a good preventative function.
  • AL721 lecithin extract
  • AL721 lecithin extract
  • Copper(II)-3,5 diisopropyl salicylate exhibits anti-ulcerogenic activity. It is a compound that can be used in an effective dosage of between approximately lOmg and about 500mg, three times a day. Copper(II)-3.5 diisopropyl salicylate is a compound which has dual efficacy having both an anti -inflammatory and some immune simulation capabilities. Generally. copper(II)-3,5 diisopropyl salicylate raises the level of superoxide dismutase, an intracellular enzyme which inhibits oxidation from taking place in the cell and may indeed function like 2- MEA. Copper(II)-3,5 diisopropyl salicylate has been largely researched for its inflammatory activity.
  • copper(II)-3,5 di-isopropyl salicylate prevents the 2-MEA from being able to cause ulcers, and augments the intracellular antioxidation effect directly by raising the superoxide dismutase levels intracellularly.
  • a preferred method is to raise a transformation factor in anticipation of the changes in the formula with 2-MEA and other compounds.
  • Copper(II)-3,5 diisopropyl salicylate was used to treat an auto-immune disease where inflammation was a problem, starting with about 30mg daily, divided into three doses of lOmg.
  • the capsule comprised about lOmg copper(II)-3,5 diisopropyl salicylate, 200g 2-MEA, lOOmg transfer factor, lOOmg BHT, and about 100-150mg of AL721.
  • Copper(II)-3,5 diisopropyl salicylate may be used by itself, in place of 2-MEA, in combination with traditional pharmaceuticals like AZT, BBI, DDC, etc., and as an adjunct to all other therapies for inflammatory diseases, malignant diseases, infectious diseases, etc. Penicillamine is used to pull out excess iron from the body. There are prescription items only, whereas 2-MEA is probably available in the stores.
  • Mutation inhibition factors and reactivation inhibition factors are defined as any factor which prevents a virus from mutating. By definition, this includes most of the above except that conventional therapies actually promote viral mutation.
  • One way the virus mutates is by marriage with and cannibalism of cellular structures, microorganism structures, and perhaps other viral structures in the system. Two things can occur if a major virus like herpes or shingles gets into the system. The he ⁇ es virus may either be reactivated by it or it may be mutated by it.
  • One way to avoid this is to use a broad spectrum of preservatives antiseptic antibiotics. BHT has a large LD50, has been be used for a long time, and is generally considered a safe product.
  • BHT augmented the antioxidant capacity of 2-MEA intracellularly and prevented additional infections, several microbial and viral infections, which would in turn control the infection that would mutate or activate the virus.
  • BHT should be combined with other microorganisms or a living biological system. This is essentially a mixture of microorganisms that cannot colonize the patient's intestine but prevent infections from coming in. These microorganisms can also be inhaled to protect your lungs and others may be rubbed onto the skin. Having a known set of microorganisms colonizing the body or monopolizing the body makes it harder for the virus to mutate in a form that you can anticipate.
  • a range of microorganisms will colonize and stabilize the microflora and prevent antigens from activating the virus through the draining of the immune function or super added infection and prevent a mutation of the virus.
  • the changes in transfer factor of synergy are not just changes that happen to the cell. The changes occur to the virus too. Two closely related viruses will always interfere strongly with each other. For example, you cannot infect bacteria with a phage and then infect it with a similar phage.
  • One way to protect T-cells against a mutated HIV is to actually infect those T-cells with a pro-virus form of HIV. If you extract out the virus from the patient when it was not breaking up his T-cells, and then inject it back into him when it is breaking up his T-cells, his own mutants of virus will compete with each other for the T- cells.
  • One way to slow down the T-cell breakdown is to re-infect the patient with the original strain which he was coping well with.
  • the original strain will compete with the mutant strain for the receptors on the cell. Once the old strain attaches to the cell, the antibodies formed will be able to destroy it. It is a way of therapeutic insertion or of constantly keeping the virus competing with its old form. It is a way of reversing the tide of mutation.
  • Levamisole, interferon, interleukin or any immune stimulants can all work in this formulation.
  • transfer factor of anticipation use can begin on the conventional therapies for AIDS which include immune stimulants which include all the other agents because, in the past, immune stimulants only caused a temporary and transient change that would pass and leave the patients in a worse state.
  • immune stimulants which include all the other agents because, in the past, immune stimulants only caused a temporary and transient change that would pass and leave the patients in a worse state.
  • transfer factors of anticipation, resistance and transformation factors when you stimulate the immune system, it will be a different system, one that is resistant to the disease and one that can anticipate the damages. You can now start using immune stimulants as well, and these will all fit into the formulation.
  • the preferred composition of this invention is the combination of 2-MEA. transfer factor. BHT, and living organism
  • Penicillin and penicillamine also have short-term activity against HIV. Very high dosages of penicillin may actually help in the treatment of AIDS patients temporarily.
  • the preferred culture techniques are techniques where organisms are made to compete for nutrients and/or one or more organisms are forced to use other organisms in culture for nutrition and/or when such nutrition is deficient in the medium and/or where one or more of the organisms is selected for by provision of its optimal needs. These can be used to develop microorganisms whole, part, or extract thereof with specific activity against targeted condition or organism. It is, therefor, possible to produce a penicillin with strong anti-HIV activity. Anticipatory vaccines against other infections which occur with AIDS can also be added to this formula.
  • Preferred culture techniques include living cells such as human and/or autogenous lymphocytes, fibroblasts, etc. which may be used in whole, part or extracts thereof.
  • Other immunostimulating, immunomodulating, inductors/augmentors of normal cellular function include immunostimulating, immunomodulating, inductors/augmentors of normal cellular function
  • Coenzyme Q10 is a powerful antioxidant, a mitochondrial antioxidant and entrocytoplasmic, which enables it to synergize with 2-MEA and copper(II)-3,5 diisopropyl salicylate and BHT. Coenzyme Q10 is also an immune stimulant.
  • T-8 cell is the suppressive cell; T-4 cell is the helper cell. T-8 counts usually raise very high in AIDS patients; the T-4 counts plummet. T-8:T-4 ratio should be a little above 1 in normal conditions.
  • the therapy may negate the effects of the chemotherapy and radiotherapy because it is a powerful antioxidant.
  • Time for administration would be 2 weeks after the chemo is given; 2-3 weeks after radiation is given. It may also raise the tolerance level of the body so you can use more chemotherapy and radiation.
  • 2- MEA and other powerful antioxidants and other anti-cancer agents such as bleomycin are more active in reduced oxidized state.
  • the chemo goes into the body, oxidizes, kills the cells, and then the 2-MEA pushes it back into reduced state, so it becomes toxic again. Parts of this formula may aggravate some chemotherapy toxicity. Smaller doses of chemo can be given by constantly reactivating it. Instead of giving bleomycin in huge doses that cause hair to fall out, you give 2-MEA and it will reactivate the bleomycin originally given.
  • Living biological system is a mixture of organisms isolated from food, but which coexist together which can synergize together and which can come into a steady state of harmony. So all of these go into the stomach and grow into an ecosystem, which is a living biological system. This is part of the 2-MEA formula or the microbial environmental stability factor. You know what the microbes will be. Living biological systems alone have an interference action with HIV and HIV co-factors and are good stimulants. They are part of the formula yet need to stand on their own. They would also help prevent ulcer formation.
  • Lactic acid bacteria (acidophilus), kefir, and rhizopus are safe, non- pathologenic organisms in a mixture whereby each, as a unit or in combination, donate beneficial features to the whole host and/or where they exist in an ecosystem which prevents superadded infection to the infiltration of the host by pathogenic organisms.
  • the organisms and strains chosen for this living biological system have specific capacity for mediating anti-cancer activity and cholesterol lowering activity, as well as organism maintenance activity.
  • the difference between living biological systems and prior art, where prior art is the administration of several strains of acidophilus, for example, or mixtures of up to 6-10 different organisms, is that a living biological system by its source and nature generally comprises more than 30 organisms.
  • Prior art consists of acidophilus, for example, in capsules, chosen for its purity and color, whereas in nature nothing exists like that.
  • Living biological systems described here are unique in a) the combination; b) the number of organisms; c) the location of the organisms. There is no other therapy which seeks to occupy structures other than the intestines, for example, of living biological systems. These can also be inserted as a nasal spray for nasal sinuses and lungs, where a living biological system can comprise viruses, bacteria, fungi, etc. For example, in the immune compromised state, phages for various bacteria can be assembled as a living biological system and inhaled on a daily or weekly basis to prevent infection with said bacteria.
  • the living biological system as described herein may be defined by its constituents or may be defined by the activity of the constituents.
  • a virus, bacteria, fungus and yeast which carry anti-cancer activity could be combined into an anti-cancer living biological system.
  • Living biological systems may exist whole or processed such that they are lysed so that whatever internal enzymatic factors may be released into the system. They can also be formulated to target specific sources and their internal nutrients can do the same, and a living biological system can be formed which would be a constant producer of by-products. For example, organisms which are capable of manufacturing vitamin C can be orally administered once a month and would continue to produce the said vitamin in body for the duration of the month.
  • Living biological systems make it possible to insert replicating forms of enzymes so that it is taken only once a month or once a year. Living biological systems may be used as mutation imagery factors and reactivation inhibitory factors.
  • One of the most powerful vaccines is the insertion of a dead feline panleukopenia virus into the blood stream of an AIDS patient. It may be because HIV functions as a hybrid of feline panleukopenia virus and hepatitis. HIV will function like a mixture of these two viruses. If you vaccinate against the function that is composed of two different things, and you upset the equilibrium by adding more of one, you disrupt the structure. HIV does not look like a simple hepatitis fused, but the theory is there.
  • Feline panleukopenia virus causes destruction of leukemia of white blood cells, as does AIDS.
  • Vaccinating against feline panleukopenia virus somehow also vaccinates against its destructive capacity, and it is similar to the AIDS destructive capacity.
  • Smallpox and vaccinia are similar viruses so you can use one to immunize against the other.
  • Bacterial phages and HIV are in no way similar, except that they can attack a cell, insert themselves into it, and cause the cell to die.
  • An AIDS infected immune system will still act against feline panleukopenia virus, and it induce cell death in only a certain number of ways, and there is an overlap between what is used by the FPLV and the HIV.
  • a living feline panleukopenia virus may not have any greater effect than a dead feline panleukopenia virus. The reason is that the living one may cause some harm to the immune system and can overcome it. Whereas a dead one will only be reactivated at the site of viral activity. If you put in a fragmented virus where a virus is actively growing, even if it is another virus, a dead virus can use the first virus's growth mechanisms to reassemble itself. If you inject feline panleukopenia virus into a body that is infected with AIDS, only the cells infected with AIDS, which have a system for growing and structuring viruses, can absorb the feline panleukopenia dead and reassemble it.
  • the virus shows up in every AIDS-infected cell ⁇ and only in every AIDS-infected cell.
  • the body can identify that and can attack it and destroy it. Particularly if the virus being used to reactivate has foreign graft antigens from the same species or different species.
  • the AIDS-infected cell now looks like a foreign cell from another source. Furthermore, specific antisera may be used against the reactivated virus and the complex that it forms.
  • 2-MEA can hold that reactivated virus, so you can vaccinate against it, raise transfer factors against the reactivated virus, use 2- MEA to hold the situation as status quo until the immune system can build up and attack it.
  • 2-MEA can be delivered by cell targets, by liposome and by agents to be uptaken by the target.
  • agents to be uptaken by the target For example, in the case of leukemia, if you want to place the 2-MEA in the normal cells but not leukemia cells, you would incubate the 2- MEA in culture with a bacteria which your body is likely to attack. Kill the bacteria and inject it into the membrane which is saturated with 2-MEA into the body. The normal white blood cells would attack it and absorb the 2-MEA, whereas the cancerous white blood cells would not respond to it. This will get 2- MEA specifically into a site where you want it. You can use any of the various ingredients. Clinical Examples of Efficacy
  • Copper(II)2,3.5-di-isopropyl salicylate was administered lOmg daily.
  • BHT was administered 600mg per day.
  • T-cell count 120 and the T4/T8 ration was 0.6.
  • the patient was treated with 2-MEA, 200mg TDS.
  • the patient was also given copper(II)-3,5-di-isopropyl salicylate, lOmg TDS; BHT at 600mg daily; living biological system as in the previously mentioned case; Also micrococcus sp and extracts were used.
  • ATP/UTP/GTP - lOmg each orally daily; multiple nutritional supplement base including enzymes, antioxidants natural and artificial, etc.; KREBS cycle nutrients ; enzymes; and cofactors.
  • the pain disappeared in 2 days. Energy levels increased within 24 hours.
  • the T-cell count was 400 and T4/T8 ratio was 1.2. Further, shrinkage of
  • Living biological systems as complicated as those mentioned here and as simple as those of acidophilus and other yogurt cultures are being patented here for use solely or in combination with other factors, agents and products thereof in the prophylaxis and treatment of the side-effects of chemotherapy and radiotherapy. It is easy to see how living systems such as those can prevent bowel flora imbalance as can be caused by such therapy and how this ability, as well as the ability to prevent opportunistic bowel infections which may follow diarrhea and/or immunosuppression precipitated by the therapy, may be beneficial. There are other mechanisms at play here, including immunostimulant properties and other anti-disease factors inherent in or inducible by the appropriate living biological systems.
  • AIDS patients with T-cell counts 400-500 were divided into two groups. Ten patients were supplemented, the other ten availed themselves of whatever therapy they had available. After a 6-year follow-up, all unsupplemented group had died; six of the ten supplemented were still alive. Improvements have been noted in multiple other conditions including arthritis, multiple sclerosis, cardiovascular disease, asthma, chronic fatigue syndrome, systemic lupus erytheromatosis, autoimmune disease, acute and degenerative diseases, infections, among others.
  • a new line of therapeutic/preventative and supplemental products where a pharmaceutical agent is bound to an infection with affinity for target organism/cell where the biological agent or fragment thereof is used for specific delivery to target; to optimize concentration of agent at target; to process the agent so as to produce useful precursors intermediates and end-products; and to augment directly or indirectly the effect required.
  • Biological delivery mechanisms may also be used to minimize irritant or other side effects of therapeutic agents.
  • 2-MEA and copper(II)-3,5 di-isopropyl salicylate can both cause local irritant effects in therapeutic levels.
  • 2 MEA has been known to cause ulcer formation.
  • Copper(II)-3,5 di-isopropyl salicylate is topically irritant.
  • a biological carrier in prior art largely reserved to the use of monoclonal antibodies; the problem here has always been one of disassociation of antibody-pharmaceutical complex and of the targeting mechanism being restricted to the delivery of agent at the superficial membrane site.
  • biopharmaceuticals includes the use of monoclonal antibodies to deliver not only therapeutic but also preventative and other agents to the target tissue (prior art covers delivery to diseased tissue); current art provides for delivery of protective and other desirable agents to healthy tissue and/or to diseases other than cancer which is the centerpiece of prior art.
  • a major variation on prior art in the use of biological mechanisms is not restricted to biological amplification and processing pathways but involved the use of antigens rather than antibodies in the preferential delivery mechanism.
  • lymphopoietic tissue may be targeted b viruses such as mumps virus or feline panleukopenia virus. Any biological/chemical or physical agent incorporated in this living system or part thereof will automatically be carried to target.
  • Chemotherapeutic agents may be carried to tumor masses including the use of anaerobic or microaerophilic organisms to deliver chemotherapeutic agents in high concentration to the center of tumor masses.
  • An example to be outlined serves to demonstrate this amplification technique as relates to immunostimulants.
  • Prior art in vaccination relates to the use of non-specific adjuvants such as that of Freunds along with vaccine to be given or the use of interferon, interleukin, etc.
  • Prior art does not include direct targeting or amplification technology.
  • biopharmaceuticals need to go after receptors whereas biopharmaceuticals go after prevailing conditions.
  • An antibody to cancer needs the cancer cell to express the antigen.
  • Biopharmaceuticals may go after a condition ie.. lack of oxygen in the center of a cancer mass. If an organism is anaerobic or microaerophilic and you saturate it with a pharmaceutical, or supplement or a genetic sequence, then the organism will go to where there is no oxygen and deliver its payload.
  • An example of the mechanism of action of biopharmaceuticals is presented below.
  • the organisms were filtered through a filter membrane, for example a 0.2 micron filter.
  • the filtrate was re-suspended and washed in normal saline.
  • the filtered fraction was re-constituted to a concentration of 10 million organisms per 1 cc. 1 ml was injected into a rate bearing Morris TC hepatoma. Following 24 hours, radiation was detected at the tumor site. After 48-72 hours, necrosis was seen at the tumor site.
  • staphylococcus aureus is incubated in a medium of trypticated soy broth for 24 hours.
  • Medium also includes 5mm of 2-MEA.
  • Identical preparation is made without the 2-MEA.
  • lOOcc of inoculated broth is then passed through a 0.2 micron filter.
  • Pellets deposited on the filter are resuspended in lOcc of normal saline then refiltered and resuspended.
  • Both a suspended in l Occ of normal saline and 5mm of 2-MEA and the full lOcc are injected into each of two horses.
  • White blood cell are collected at 3 hours, 24 hours and 14 days.
  • Crude transfer factor extract was prepared by freezing, thawing and 0.2 micron filtration of l OOcc of white blood cells suspended in normal saline at concentration of ten million cells per cc.
  • One cc of transfer factor was fed to Balb C mice every day for 10 days followed by bacterial cell challenge.
  • One cc containing 10 million organisms of the original staphylococcus lethargy was noted for 1-3 days but no abscesses developed.
  • Control group of 10 mice was inoculated intramuscularly. These were evaluated after 10 days. Six of the mice developed abscesses locally. All demonstrated lethargy for several days after inoculation.
  • transfer factor was more effective from the horse treated with the 2-MEA suggested a specific stimulation of appropriate cellular response.
  • transfer factor demonstrated no marked increase in efficacy, although transfer factor yield may have been greater than the control yield.
  • An extension of this invention is the feeding of transfer factor in culture preparation of vaccine and/or provision concomitantly to increase efficacy of therapy.
  • Copper di-isopropyl salicylate can induce production of superoxide dismutase.
  • a biological delivery system such as living human/animal cells or various microorganisms such as yeast will enable not only targeted delivery of the compound but can also generate superoxide dismutase and/or other antioxidant enzymes as active factors.
  • Biological active factors may be amplified by exposure to an oxidant such as 2% peroxide. Following generation of antioxidant enzymes, the peroxide may be neutralized by antioxidants such as vitamin C.
  • targeting complex may be used whole or in part, living or inactivated by physical, chemical or biological agents such as ultrasound, phenol or enzymatic degradation.
  • Use of biological delivery mechanisms also enables the topical application of such products for cosmetic, protective and other effects.
  • One modality of application involves the absorption, activation and application of 2-MEA and copper di-isopropyl salicylate into target cells such as yeast or lactobacilh or human cells with 2-MEA and grown into a culture.
  • target cells such as yeast or lactobacilh or human cells with 2-MEA and grown into a culture.
  • Human cells and/or autogenous cells of skin, blood or other source may be cultured in vitro and suspended live or killed in a cosmetic base or yogurt base.
  • Culture techniques may dedifferentiate cell types and/or may be used to stress the cells or manipulate in other ways to produce antioxidant and other beneficial enzymes and factors. Manipulation of temperature will yield to factors protective against heat and cold, as well as moisture loss, if that is made a condition of culture.
  • cells may be returned to friendly antioxidized environment to reduce free radicals. Cells are then disrupted or fixed so as to maintain all beneficial factors and not allow for their return to original parameters. In living or dead state, such cells will maintain genetic and other response modalities which may prove beneficial as therapy/prevention/ supplementation or topical application to recipient.
  • Various donor systems may yield beneficial properties but autogenous cells which have been manipulated or augmented in a physical/chemical or biological manner enable greater interaction and protection of recipient.
  • Cells suffer radiation damage, for example, when exposed to frequencies that are absorbed by vital cellular fractions such as the DNA and those structure are damaged. It is possible to evaluate the sites most frequently damaged and prepare a topical concentrate of the same or similar structures to shield the body. It is also possible to anticipate the exposure and make preparations from cells that service such exposure to confer protection and it is possible to use the whole cell, genetic fractions or other fractions to confer the resistance. Autogenous cells, however, provide the best matching of DNA and other susceptible fractions. Addition of 2-MEA to the culture media can increase their resistance to radiation and other factors, thus providing for greater shielding. Copper(II) 3,5 di-isopropyl salicylate and other antioxidants may also similarly be used.
  • Autogenous cosmetics can also include immune cell amplification from blood used a cosmetic to combat pimples. Again, this invention covers the concept of the use of living systems or fragments thereof to provide shielding or protection against particular challenge or disorder. Autogenous cells ensure minimal allergic responses, improved efficacy and bioavailability. Use of 2- MEA and related aminothiols and/or copper(II) 3,5 di-isopropyl salicylate and other di-isopropyl salicylates, as well as other factors, may amplify and augment efficacy.
  • Such preparations particularly autogenous may shield normal cells from radiotherapy by coating the outside of the body with counte ⁇ arts which have been augmented and/or amplified to receive harmful frequencies, whether on the body or fixed in a shield/filter between the beam source and the body.
  • Normal structures should be spared at least some damage and optimal damage to disease-specific structures achieved.
  • the agent can be processed and presented to the body in a more effective form such as precursors, intermediates and end products.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne de nouvelles compositions et applications de 2-mercaptoéthanolamine (2-MEA) et d'aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (II). Ces compositions sont utilisées seules ou en association avec d'autres facteurs, agents ou procédés physiques, chimiques et/ou biologiques. Il peut s'agir de précurseurs, d'intermédiaires, de produits finis, de catalyseurs, de promoteurs et/ou d'autres facteurs, agents ou procédés mis en jeu directement ou indirectement depuis l'application initiale de la composition jusqu'à l'obtention du résultat recherché.
EP96931214A 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies Withdrawn EP0858327A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US428195P 1995-09-25 1995-09-25
US4281P 1995-09-25
PCT/IB1996/001059 WO1997011666A2 (fr) 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies

Publications (1)

Publication Number Publication Date
EP0858327A2 true EP0858327A2 (fr) 1998-08-19

Family

ID=21710013

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96931214A Withdrawn EP0858327A2 (fr) 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies
EP96932773A Withdrawn EP0853486A4 (fr) 1995-09-25 1996-09-25 Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP96932773A Withdrawn EP0853486A4 (fr) 1995-09-25 1996-09-25 Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes

Country Status (5)

Country Link
EP (2) EP0858327A2 (fr)
JP (1) JPH11514990A (fr)
AU (2) AU7143196A (fr)
CA (2) CA2233015A1 (fr)
WO (2) WO1997011667A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DK1220678T3 (da) * 1999-10-04 2007-07-09 John Carter Farmaceutiske præparater indeholdende kobber, salicylsyre og C-vitamin
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
FR2825923B1 (fr) * 2001-06-15 2006-04-07 Oreal Inhibiteur de no-synthase et utilisations
KR20030077743A (ko) * 2002-03-26 2003-10-04 변현규 In½
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
WO2004024129A1 (fr) * 2002-09-10 2004-03-25 Samir Chachoua Therapie induisant une remission
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
CN101138634A (zh) 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
WO2009070788A1 (fr) 2007-11-30 2009-06-04 The Ramaekers Family Trust Compositions et procédés d'amélioration de la fertilité
WO2010093606A1 (fr) * 2009-02-11 2010-08-19 Martin Heath Bluth Echange réciproque sérum/plasma pour le traitement du cancer
CN107106531A (zh) 2014-11-26 2017-08-29 于保法 微创精准个体化肿瘤内化学诱导免疫治疗方法半抗原增强的化学免疫治疗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
US5310653A (en) * 1989-10-24 1994-05-10 Board Of Regents, The University Of Texas System Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
WO1994028934A1 (fr) * 1993-06-07 1994-12-22 Center For Special Immunology Traitement adoptif de reconstitution immunitaire pour des patients atteints d'immunodeficiences acquises

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9711666A2 *

Also Published As

Publication number Publication date
EP0853486A2 (fr) 1998-07-22
AU6999096A (en) 1997-04-17
WO1997011667A2 (fr) 1997-04-03
AU7143196A (en) 1997-04-17
JPH11514990A (ja) 1999-12-21
CA2233015A1 (fr) 1997-04-03
WO1997011667A3 (fr) 1997-06-12
WO1997011666A2 (fr) 1997-04-03
WO1997011666A3 (fr) 1997-06-19
EP0853486A4 (fr) 2001-09-26
CA2233445A1 (fr) 1997-04-03

Similar Documents

Publication Publication Date Title
EP0858327A2 (fr) Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies
EP2286832B1 (fr) Compositions bactériennes pour le traitement du cancer
US20200384040A1 (en) Use of bacteroides fragilis in preparation of medicament for treating and preventing tumor
Renoux et al. Potentiation of T-cell mediated immunity by levamisole.
Siveen et al. Augmentation of humoral and cell mediated immune responses by Thujone
KR20030081445A (ko) 세포 사멸을 조절하는 세포독성인자
Teixeira et al. Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes
Dhuley Therapeutic efficacy of Ashwagandha against experimental aspergillosis in mice
US6258847B1 (en) Use of 2-mercaptoethanolamine (2-MEA) and related aminothiol compounds and copper(II)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
Farber Clinical and biological studies with actinomycins
WO2017222295A1 (fr) Composition pour la prévention et le traitement du virus de la grippe, comprenant des bactéries lactiques dérivées du kimchi et de la pâte de soja comme ingrédient actif
Polk The enhancement of host defenses against infection—Search for the Holy Grail?
UA79952C2 (en) MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AU2004200804A1 (en) Use of 2-Mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(II)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various disease
Erciyas Murrembeena (AU)
Malkov et al. Antitumor features of Bacillus oligonitrophilus KU-1 strain
Kobayashi et al. Biphasic protection against bacterial infection in mice induced by vaccination of Propionibacterium acnes
Engle et al. Rifampin inhibition of H-1 virus infection in hamsters
WO2008054293A1 (fr) Composition, utilisation de ladite composition pour le traitement de maladies et d&#39;états systémiques, et produit contenant ladite composition
JPH07238024A (ja) 好中球機能改善剤
Nowotny et al. Studies on host defenses enhanced by endotoxins: a brief review
Miura et al. Effects of levamisole administration on treatment with 6-mercaptopurine riboside of mice bearing L1210 leukemia cells
JPS5946487B2 (ja) 免疫強化剤
OKURA et al. Effect of forphenicinol on the production of Ia-positive macrophages in mice with or without L1210 leukemia and on the growth of L1210 in immunized mice
Hoffmann et al. Antiproliferative effect of retinoids and interferon α in combination with irradiation on human tumor cell lines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980424

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010403

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1015679

Country of ref document: HK